OBI Pharma, Inc.

OBI Pharma, Inc.  is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.

In 2018 it announced that its drug, OBI-3424, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC).

History
The company was founded by Micheal N.Chang on April 29, 2002. It was formerly a subsidiary of Optimer Pharmaceuticals.

On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange. At that time, its share price was US$8.50 per share.

On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan.

On 23 Mar 2015, it can do transaction formally on OTC in Taiwan R.O.C.

Primary Focus
The company mainly concentrates on the development of the research and development of cancer therapies and high quality drugs.